Search results for "ASAT"

showing 10 items of 96 documents

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Mediator-Induced Changes in Macromolecular Permeability in the Rat Mesenteric Microcirculation

1995

An intravital fluorescence microscopic method for measurement of changes in macromolecular permeability has been established in the mesenterial microcirculation of the rat. After exteriorization of the fat-free distal part of the ileal mesentery, a 1-hr period of stabilization was followed by the injection of FITC-labeled macromolecules. Five minutes later, histamine, leukotriene B4, or leukotriene C4 was topically applied to the tissue by means of a micromanipulator. Areas of 1 mm2 were videotaped with a SIT camera. The fluorescence intensity of these areas was measured by an analogous video image processing system and displayed as gray value histograms. The shift of the frequency of gray …

MaleLeukotrienesPathologymedicine.medical_specialtyMacromolecular SubstancesLeukotriene B4Histamine AntagonistsRats Inbred WFVascular permeabilityBiochemistryMicrocirculationCapillary PermeabilityRats Sprague-Dawleychemistry.chemical_compoundmedicineAnimalsMesenteryLeukotrieneMicroscopy VideoLeukotriene C4MicrocirculationDextransCell BiologyExtravasationRatsLight intensityMicroscopy FluorescencechemistryBiophysicsFemaleCardiology and Cardiovascular MedicineBlood Flow VelocityFluorescein-5-isothiocyanateHistamineHistamineMicrovascular Research
researchProduct

Comparison of two histopathologic methods for evaluating subcutaneous reaction to mineral trioxide aggregate

2011

Objectives: One of the most important factors for suitable materials for pulp therapy is biocompatibility. Two histopathologic methods of Cox and Federation Dentaire International (FDI) were used to evaluate inflammation. In Cox method, density of inflammatory cells, tissue reactions like fibrosis, vascular responses like congestion and fibrin extravasation have been used to evaluate inflammatory reactions. The aim of this study was to compare the accuracy of pathologists’ interpretations using two different methods. Study design: Three pathologists observed the degree of inflammation in 225 histopathologic sections. These sections showed inflammation in subcutaneous connective tissue of ra…

MaleMineral trioxide aggregatePathologymedicine.medical_specialtySubcutaneous connective tissueConnective tissueRoot Canal Filling MaterialsSubcutaneous TissueFibrosismedicineAnimalsRats WistarAluminum CompoundsGeneral DentistryInflammationOral Medicine and PathologyPathology ClinicalKappa valuebusiness.industrySilicatesOxidesCalcium Compounds:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseExtravasationRatsDrug Combinationsmedicine.anatomical_structureOtorhinolaryngologyPulp therapyUNESCO::CIENCIAS MÉDICASResearch-ArticleSurgerybusinessSubcutaneous tissue
researchProduct

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2006

The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy.We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events.The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best …

MaleOncologymedicine.medical_specialtyFusion Proteins bcr-ablAntineoplastic AgentsKaplan-Meier EstimateChronic phase chronic myelogenous leukemiaDisease-Free SurvivalPiperazineschemistry.chemical_compoundLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOmacetaxine mepesuccinatemedicineHumansneoplasmsbusiness.industryPonatinibCytarabineInterferon-alphaMyeloid leukemiaImatinibGeneral MedicineProtein-Tyrosine KinasesSurvival AnalysisSurvival RateDasatinibPyrimidinesTreatment OutcomeImatinib mesylatechemistryNilotinibBenzamidesImmunologyImatinib MesylateFemalebusinessFollow-Up Studiesmedicine.drugNew England Journal of Medicine
researchProduct

Kinetics of Photofrin II in perifocal brain edema.

1993

Photodynamic therapy is under intense investigation as a possible adjuvant for the treatment of malignant tumors of the central nervous system. It relies on the fact that photosensitizers are selectively taken up or retained by malignant tissue. However, most brain tumors are accompanied by substantial vasogenic edema as a consequence of blood-brain barrier disruption within the tumor, leading to extravasation and propagation of plasma constituents into the surrounding brain tissue. Systemically administered photosensitizers may enter healthy tissue together with the edema fluid, possibly leading to sensitization of tissues outside the tumor. To test this hypothesis, vasogenic edema was ind…

MalePathologymedicine.medical_specialtymedicine.medical_treatmentCentral nervous systemPhotodynamic therapyBrain EdemaCerebral edemaLesionchemistry.chemical_compoundEdemamedicineAnimalsPhotosensitizerTissue DistributionRats WistarFluorescein isothiocyanatebusiness.industryBrain Neoplasmsmedicine.diseaseExtravasationRatsCold TemperatureDisease Models Animalmedicine.anatomical_structurechemistryMicroscopy FluorescencePhotochemotherapySurgeryDihematoporphyrin EtherNeurology (clinical)medicine.symptombusinessFluorescein-5-isothiocyanateExtravasation of Diagnostic and Therapeutic MaterialsNeurosurgery
researchProduct

Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation,…

1996

There is currently interest in the potential use of selective inhibitors of cyclic nucleotide phosphodiesterases (PDE) in the treatment of asthma. In this study we examined the effects of three selective PDE inhibitors, milrinone (PDE III), rolipram (PDE IV) and zaprinast (PDE V), on the broncoconstriction produced by antigen and histamine, the airway hyperreactivity and microvascular leakage after aerosol exposure to platelet-activating factor (PAF) and antigen, and the antigen-induced eosinophil infiltration in guinea-pig lung. Inhaled rolipram (0.01-10 mg ml-1) inhibited dose dependently the bronchospasm produced by aerosol antigen (5 mg ml-1) an anaesthetised, ventilated guinea-pigs. Ro…

MalePhosphodiesterase InhibitorsGuinea PigsRespiratory SystemPharmacologychemistry.chemical_compoundmedicineAnimalsPlatelet Activating FactorRolipramPharmacologyPlatelet-activating factorDose-Response Relationship DrugChemistryPhosphodiesteraseGeneral Medicinerespiratory systemExtravasationAsthmaPyrrolidinonesEosinophilsImmunologyMilrinoneBronchoconstrictionmedicine.symptomZaprinastRolipramHistaminemedicine.drugHistamineNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer.

2021

Platinum-based chemotherapy remains widely used in advanced non-small cell lung cancer (NSCLC) despite experimental evidence of its potential to induce long-term detrimental effects, including the promotion of pro-metastatic microenvironments. In this study, we investigated the interconnected pathways underlying the promotion of cisplatin-induced metastases. In tumor-free mice, cisplatin treatment resulted in an expansion in the bone marrow of CCR2+CXCR4+Ly6Chigh inflammatory monocytes (IMs) and an increase in lung levels of stromal SDF-1, the CXCR4 ligand. In experimental lung metastasis assays, cisplatin-induced IMs promoted the extravasation of tumor cells and the expansion of CD133+CXCR…

MaleReceptors CXCR4Stromal cellLung NeoplasmsSettore MED/08 - Anatomia PatologicaMonocytesMetastasisMiceCarcinoma Non-Small-Cell LungCell Line TumorDrug DiscoveryGeneticsMedicineSettore MED/05 - Patologia ClinicaAnimalsHumansDrug InteractionsAC133 AntigenNeoplasm MetastasisLung cancerMolecular BiologyPharmacologyCisplatinCXCR4 antagonistchemotherapy combination therapy inflammatory monocytes lung cancer stem cells metastasis peptide anti-CXCR4 SDF-1/CXCR4 axisbusiness.industrymedicine.diseasePrimary tumorXenograft Model Antitumor AssaysExtravasationChemokine CXCL12medicine.anatomical_structureRAW 264.7 CellsA549 CellsCancer researchNeoplastic Stem CellsMolecular MedicineBone marrowCisplatinbusinessPeptidesmedicine.drugMolecular therapy : the journal of the American Society of Gene Therapy
researchProduct

Effectiveness of oral N -acetylcysteine in a rat experimental model of asthma

2002

Oxidative stress appears to be relevant to asthma pathogenesis. Therefore, the effectiveness of the antioxidant N -acetylcysteine was examined on antigen-induced pulmonary responses in sensitized Brown-Norway rats. N -acetylcysteine (oral, 1 mmol kg(-1)per day for 7 days before challenge) did not reduce the immediate bronchospasm that followed aerosol antigen exposure but prevented airway hyperreactivity to 5-hydroxytryptamine at 24 h after antigen challenge, and reduced the eosinophils (from 0.178 +/- 0.038 in the absence to 0.064 +/- 0.020 x10(6)cells ml(-1)in the presence of N -acetylcysteine;P< 0.05), and Evans blue dye extravasation in bronchoalveolar lavage fluid. Taurine levels in br…

MaleTaurineBronchoconstrictionLung injuryPharmacologyBronchospasmAcetylcysteinechemistry.chemical_compoundRats Inbred BNmedicineAnimalsAntigensEvans BluePharmacologyDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryFree Radical Scavengersrespiratory systemAsthmaExtravasationAcetylcysteineRatsrespiratory tract diseasesEosinophilsDisease Models AnimalDose–response relationshipBronchoalveolar lavagechemistryImmunologymedicine.symptombusinessBronchoalveolar Lavage FluidEvans BlueExtravasation of Diagnostic and Therapeutic Materialsmedicine.drugPharmacological Research
researchProduct

Neuroprotection by erythropoietin administration after experimental traumatic brain injury.

2007

A large body of evidence indicates that the hormone erythropoietin (EPO) exerts beneficial effects in the central nervous system (CNS). To date, EPO's effect has been assessed in several experimental models of brain and spinal cord injury. This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI. Experimental TBI was induced in rats by a cryogenic injury model. rHuEPO or placebo was injected intraperitoneally immediately after the injury and then every 8 h until 2 or 14 days. Forty-eight hours after injury brain water content, an indicator of brain edema, was measured with the wet-dry method and bl…

MaleTime FactorsBrain EdemaFunctional LateralityRats Sprague-Dawleychemistry.chemical_compoundTraumatic brain injuryMedicineAnalysis of Variance Animals Blood-Brain Barrier; drug effects Brain Edema; drug therapy/etiology Brain Infarction; drug therapy/etiology Brain Injuries; complications/drug therapy Disease Models; Animal Erythropoietin; administration /&/ dosage Evans Blue; diagnostic use Functional Laterality Humans Male Neurologic Examination Neuroprotective Agents; administration /&/ dosage Rats Rats; Sprague-Dawley Reaction Time; drug effects Recombinant Proteins Time Factorsadministration /&/ dosageSpinal cord injuryEvans BlueNeurologic ExaminationGeneral Neuroscienceexperimental models of brain and spinal cord injuryExtravasationNeuroprotectionRecombinant Proteinsmedicine.anatomical_structureNeuroprotective AgentsBlood-Brain BarrierAnesthesiadiagnostic usemedicine.drugEvans BlueBrain InfarctionTraumatic brain injuryCentral nervous systemrecombinant human EPO (rHuEPO)PlaceboNeuroprotectionReaction TimeAnimalsHumansMolecular BiologyErythropoietinAnalysis of VarianceNeuroscience (all)business.industryAnimaldrug therapy/etiologymedicine.diseaseRatsDisease Models AnimalchemistryErythropoietindrug effectsBrain InjuriesDisease Modelsrecombinant human EPO (rHuEPO); experimental models of brain and spinal cord injury; NeuroprotectionNeurology (clinical)Sprague-Dawleybusinesscomplications/drug therapyDevelopmental BiologyBrain research
researchProduct

Blood-brain barrier disruption by low-frequency ultrasound.

2006

Background and Purpose— A recent study showed a dramatic increase in cerebral hemorrhage comprising atypical locations with low-frequency ultrasound–mediated recombinant tissue plasminogen activator–thrombolysis in humans. Here, we provide a possible explanation for this phenomenon by a side effect observed in a study using the similar ultrasound device. Methods— The study was originally undertaken to investigate by transcranial Doppler sonography, positron emission tomography and perfusion MRI whether transcranial application of wide-field low-frequency ultrasound (300 kHz) improves cerebral hemodynamics in patients with cerebral small vessel disease. Results— Showing no clear positive ef…

Malemedicine.medical_specialtyUltrasonography Doppler TranscranialUltrasonic TherapyPerfusion scanningBrain IschemiaBrain ischemiaParietal LobemedicineHumansCerebral perfusion pressureStrokeAgedAdvanced and Specialized Nursingmedicine.diagnostic_testbusiness.industryUltrasoundHemodynamicsMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance ImagingFrontal LobePositron emission tomographyBlood-Brain BarrierCerebrovascular CirculationPositron-Emission TomographyNeurology (clinical)RadiologyCardiology and Cardiovascular MedicinebusinessPerfusionExtravasation of Diagnostic and Therapeutic MaterialsStroke
researchProduct